The stock of VANC Pharmaceuticals Inc (CVE:VANC) is a huge mover today! About 69,800 shares traded hands or 12.87% up from the average. VANC Pharmaceuticals Inc (CVE:VANC) has risen 6.00% since October 31, 2016 and is uptrending. It has outperformed by 0.77% the S&P500.
The move comes after 5 months positive chart setup for the $4.05M company. It was reported on Nov, 30 by Barchart.com. We have $0.28 PT which if reached, will make CVE:VANC worth $162,000 more.
More notable recent VANC Pharmaceuticals Inc (CVE:VANC) news were published by: Marketwired.com which released: “VANC Pharmaceuticals Signs Definitive Agreement for Exclusive In-License on a …” on June 20, 2016, also Marketwired.com with their article: “Vanc Pharmaceuticals Announces Launch of New OTC Product and Provides Update …” published on May 02, 2016, Marketwired.com published: “VANC Pharmaceuticals Announces Corporate Update and Launch of Hema-Fer” on March 07, 2016. More interesting news about VANC Pharmaceuticals Inc (CVE:VANC) were released by: Marketwired.com and their article: “VANC Pharmaceuticals Receives Health Canada Approval for Van-Fer Tablets and …” published on June 21, 2016 as well as Marketwired.com‘s news article titled: “Vanc Pharmaceuticals Launches First OTC Product in British Columbia” with publication date: December 07, 2015.
VANC Pharmaceuticals Inc. is engaged in the manufacturing and distribution of generic and over-the-counter pharmaceuticals. The company has a market cap of $4.05 million. The Company’s OTC products division is engaged in the manufacture and sales of OTC healthcare products, which are used for the prevention and treatment of various chronic ailments and conditions. It currently has negative earnings. The Company’s Health Canada-approved, OTC products are Hema-fer (premium natural iron supplement for iron deficiency and anemia) and Cortivera (hydrocortisone cream/ointment in combination with Aloe Vera).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.